Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.86 |
| ▸ | MC4R | P32245 | 1/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | CHKA | P35790 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577331 | 1.00 | SIGMAR1 (0.86) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1043563 | 1.00 | SIGMAR1 (0.86) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL576379 | 1.00 | SIGMAR1 (0.86) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2228267 | 0.98 | SIGMAR1 (0.81) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1045330 | 0.98 | SIGMAR1 (0.81) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL329650 | 0.98 | SIGMAR1 (0.81) | SIGMAR1MC4RDRD4LMNAPOLB | |
| Water SCHEMBL17460165 | 0.95 | SIGMAR1 (0.77) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL3061933 | 0.94 | SIGMAR1 (0.75) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL13952 | 0.93 | SIGMAR1 (0.81) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1777747 | 0.93 | SIGMAR1 (0.81) | SIGMAR1MC4RDRD4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269995-B1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DAINIPPON INK & CHEMICALS (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8017706-B2 | Process for production of polymers with iron complex catalyst | DIC CORPORATION (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporatio (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2269995-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | DIC Corporation (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105703-A1 | PROCESS FOR PRODUCTION OF POLYMERS WITH IRON COMPLEX CATALYST | TFRC, FECH, FTH1 | SIGMAR1 886/4885MC4R 2085/4885DRD4 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.